Novartis Ag (NVS) EBITDA Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -164.00 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -611.00 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -572.00 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | -194.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | -341.00 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | -538.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -164.00 |
| Mar 31, 2026 | -294.00 |
| Dec 31, 2025 | 1,504.00 |
| Sep 30, 2025 | 408.00 |
| Jun 30, 2025 | 253.00 |
| Mar 31, 2025 | -860.00 |
| Dec 31, 2024 | -125.00 |
| Sep 30, 2024 | 1,333.00 |
| Jun 30, 2024 | 754.00 |
| Mar 31, 2024 | -92.00 |
| Dec 31, 2023 | 155.00 |
| Sep 30, 2023 | -245.00 |
| Jun 30, 2023 | 711.00 |
| Mar 31, 2023 | 2,199.00 |
| Dec 31, 2022 | -366.00 |
| Sep 30, 2022 | -741.00 |
| Jun 30, 2022 | -942.00 |
| Mar 31, 2022 | 330.00 |
| Dec 31, 2021 | 167.00 |
| Sep 30, 2021 | 514.00 |